Today: 19 March 2026
Subscribe
Browse Category

NYSE:NUE 15 November 2025 - 1 February 2026

Basic Materials Stocks Slide After Metal Selloff — What to Know Before Monday’s Open

Basic Materials Stocks Slide After Metal Selloff — What to Know Before Monday’s Open

The iShares U.S. Basic Materials ETF fell 3.3% to $170.29 Friday, closing the week below its 52-week high after a sharp metals selloff. U.S.-listed gold and silver miners led declines as China’s manufacturing PMI dropped to 49.3, missing forecasts. Freeport-McMoRan slid 7.5%, while Air Products and Chemicals jumped 6.5% on earnings. Investors await U.S. and China economic data for direction.
1 February 2026
·····
Trump’s Tariff Tsunami: 100% Drug Tax and New Import Levies Rock Global Trade

Trump’s Tariff Shockwave: 2025 Trade War Revival Rocks Global Markets and Economy

President Trump reimposed and expanded tariffs in 2025, including a universal 10% tariff on all imports and 25% duties on autos, sparking global retaliation. U.S. steel stocks surged, but automakers cut jobs and faced supply disruptions. The MSCI World index dropped 10% after the April tariffs, then rebounded. U.S. GDP shrank 0.5% in Q1; tariffs added about $1,200 in annual costs per household.
15 November 2025
···

Stock Market Today

  • Soligenix Publishes HyBryte Clinical Data Validating Safety and Efficacy
    March 19, 2026, 2:04 PM EDT. Soligenix (NASDAQ: SNGX), a biopharmaceutical firm targeting rare diseases, reported the publication of clinical trial data on HyBryte (synthetic hypericin) in the peer-reviewed journal Expert Opinion on Investigational Drugs. The summary underscores HyBryte's safety profile, non-mutagenic mechanism, and demonstrated efficacy against cutaneous T-cell lymphoma (CTCL). The data supports HyBryte's potential as a first-line treatment. Soligenix continues its ongoing FLASH2 Phase 3 trial for HyBryte, with an interim analysis slated for Q2 2026. The company focuses on rare disease therapies and vaccine programs underpinned by proprietary technology. This publication bolsters investor confidence as Soligenix advances regulatory efforts toward global commercialization of HyBryte, expanding its pipeline across inflammatory and infectious diseases.
Go toTop